Biotech is one of the most challenging industries for investors. Dominated by small-cap companies with capital intensive operations, binary catalysts, and a low probability of ever generating revenue, most would be wise to avoid it entirely.

However, there is a population of investors and hedge funds who specialize, sometimes exclusively, in the biotech sector. And some are fantastically successful. We call these investors biotech specialists.

At RxDataLab, we maintain a hand-picked list of these specialists to monitor their buying patterns, allowing us to identify promising therapeutic areas and structural investing trends early (for instance see our recent piece on Edgewise Therapeutics and Duchenne muscular dystrophy).

Pioneering work by Verdad Capital identified specialist concentration as a powerful signal for their quantitative biotech strategy. Following their approach, we wanted to answer a broader set of questions: how many biotech specialists exist in the wild, and how has this population shifted over time?

To address this, we built a systematic screening pipeline of every institutional 13F filer since Q2 2013. We call the resulting dataset the Biotech Specialist Investor Census.

Browse all 287 funds in the searchable registry table.

Identifying the Biotech Specialists #

To build our database, institutional funds must meet two baseline criteria:

• Concentration: Holds more than 60% of their reported 13F assets in biotech-classified companies (spread across more than one holding)
• Scale: Manages more than 100 million (sum of reported holdings on 13F, not necessarily total firm AUM)

Once qualified, we divide the population into three distinct tiers based on reported concentration:

• Pure-Play Specialists (≥90% Biotech): Funds whose sole focus is the life sciences sector.

• Focused Investors (60% to 90% Biotech): Dedicated sector investors who retain modest flexibility to invest outside biotech.

• Tactical Allocation (30% to 60% Biotech): Generalist or healthcare-broad funds with meaningful exposure, but not a strict biotech-only focus.

Biotech Specialists are Rare and Persistent #

As of Q4 2025, there are 101 Pure-Play specialists, 37 Focused Investors, and 55 as Tactical Allocators.

Over time, the Pure-Play tier has grown steadily from near zero at the start of our study period to an all-time high of 101 in Q4 2025. This is still a vanishingly small 1.2% of all 13F filers. This cohort is also persistent, with little change during challenging periods for biotech such as 2022.

In contrast, the Focused Investor tier (60 - 90%) peaked at 66 funds in Q4 2021, at the height of the COVID-era biotech boom, then collapsed as market conditions deteriorated. It has not recovered, sitting at just 37 funds today.

Biotech Specialist Lifecycles #

Not every fund that qualifies as a specialist stays active. Of the 287 entities that have met the ≥60% specialist threshold, here is where they stood as of 2025 Q4:

Entry and exit patterns track the macro biotech cycle closely. 2020 was the peak entry year with 36 new funds crossing the specialist threshold, while 2024 marked the first year with net-negative fund growth (24 exits against 18 entrants).

Pure-Play Specialist #

15 funds have held ≥60% biotech for nearly the entire study period, regardless of current tier. Three of those (Opaleye Management, Rhenman & Partners, Sector Gamma) have since drifted into the 60–90% Focused tier, and one (Essex Woodlands Management) is a PE/VC vehicle rather than a public-markets hedge fund and is excluded below.

The eleven remaining funds that have been biotech specialists for nearly the entire study period and remain in the top Pure-Play tier (≥90% biotech) today:

• Baker Bros. Advisors
• BVF Partners
• Palo Alto Investors
• Sectoral Asset Management
• Tang Capital Management
• RA Capital Management
• Perceptive Advisors
• Redmile Group
• OrbiMed Advisors
• Cormorant Asset Management
• Great Point Partners

Strategy Beyond 13F #

The population of Pure-Play biotech specialists is a very small portion of all 13F filers, but is steadily growing. Here we described identifying and monitoring patterns of biotech investing since 2013. However, identification is only the first step. Many of these funds have distinct investing styles (e.g., 13D activist positions) and most of the recognizable Pure-Play funds are heavily engaged in private venture investing and company-building. A good example is Perceptive Advisors, who report only ~18% of their $11.77 billion portfolio as publicly traded equities, or RA Capital Venture (aka Raven). Biotech specialists are known to make heavy use of warrants and PIPE’s as well. RxDataLab is providing the list of funds in a table below, and we will be diving deeper into investing styles in the near future. In the meantime, we also monitor 13D and 13G filings from the investors identified here at RxDataLab’s BioHedge dashboard.

Reach out to [email protected] with questions or comments!

Interactive Fund Table

The table below includes all 287 entities that have ever met the specialist threshold (≥60% biotech, >1 position, ≥$100M total equity), with their most recent filing data and lifecycle status.

Methodology Notes #

Manual Exclusions: A small number of entities meeting the quantitative criteria are manually stripped out because they are not traditional investment managers. Excluded categories include strategic pharma corporate venture arms (Pfizer, Sanofi, Gilead, etc.), large university or charitable foundations (UC Regents, Memorial Sloan Kettering), trust departments tracking passive insider holdings, or individuals filing personal 13Fs.

CIK vs. Firm Analysis: 13F filings are registered at the institutional advisor level, meaning multiple sub-funds under the same parent company may count as separate entries (e.g., separate Foresite Capital fund vehicles). We manually combine fund vehicles where possible at our discretion.

Venture Capital Distinctions: Venture capital firms (ARCH, Third Rock, Flagship, Atlas) are captured here because their public IPO positions scale past our asset threshold, though their trading mechanics differ significantly from public market hedge funds.

Defining a Biotech Holding: A position is tagged as biotech if (1) the CUSIP matches an asset in the RxDataLab clinical trial tracking ecosystem, or (2) the company name utilizes explicit industry keywords (Therapeutics, Biologics, Oncology). Large-cap biopharma giants with active clinical pipelines (Moderna, Amgen, Regeneron) are included; traditional, highly-diversified consumer health conglomerates are not.

13F Data Boundaries: 13F forms only represent long public equity positions. They omit private placements, venture equity, convertible debt structures, or short positions. All data is subject to the standard SEC 45-day post-quarter reporting lag. RxDataLab tracks Schedule 13D and G filings, and Form 4 which provide more timely activity metrics.

For more details on RxDataLab see our about, methodology, and philosophy.